US EditionBELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer
Summary by curetoday.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Trial to test relacorilant combo in platinum-resistant ovarian cancer
Corcept Therapeutics is launching a Phase 2 clinical trial to evaluate the safety and efficacy of relacorilant as a triple combination treatment — with the therapies nab-paclitaxel and bevacizumab — in people with platinum-resistant ovarian cancer, according to a company press release. The open-label BELLA trial (NCT06906341) trial expects to enroll 90 women with recurrent, platinum-resistant ovarian cancer at about 50 sites in North America, Eu…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage